Your browser is no longer supported. Please, upgrade your browser.
HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite Help
publish chart | save to portfolio | create alert Type: candle | line | advanced | interactive | perf    Timeframe: intraday | daily | weekly | monthly  Settings
ITRM Iterum Therapeutics plc daily Stock Chart
ITRM [NASD]
Iterum Therapeutics plc
Healthcare | Biotechnology | Ireland
statements
Index- P/E- EPS (ttm)-6.75 Insider Own0.30% Shs Outstand14.87M Perf Week-4.24%
Market Cap23.94M Forward P/E- EPS next Y-2.17 Insider Trans-88.72% Shs Float11.18M Perf Month-22.07%
Income-98.70M PEG- EPS next Q-0.87 Inst Own41.90% Short Float3.44% Perf Quarter-59.79%
Sales0.00M P/S- EPS this Y-32.40% Inst Trans-15.24% Short Ratio0.34 Perf Half Y-71.89%
Book/sh-2.81 P/B- EPS next Y31.30% ROA-207.40% Target Price- Perf Year-82.98%
Cash/sh1.16 P/C0.98 EPS next 5Y- ROE848.60% 52W Range1.12 - 7.65 Perf YTD-74.89%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-85.23% Beta-
Dividend %- Quick Ratio0.60 Sales past 5Y- Gross Margin- 52W Low0.89% ATR0.12
Employees44 Current Ratio0.60 Sales Q/Q- Oper. Margin- RSI (14)30.00 Volatility5.38% 7.26%
OptionableNo Debt/Eq- EPS Q/Q24.80% Profit Margin- Rel Volume0.58 Prev Close1.13
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume1.15M Price1.13
Recom3.00 SMA20-17.71% SMA50-52.07% SMA200-60.76% Volume0 Change0.00%
Jun-02-20Downgrade RBC Capital Mkts Outperform → Sector Perform $7 → $2
Jan-21-20Downgrade Gabelli & Co Buy → Sell
Dec-11-19Downgrade SVB Leerink Outperform → Mkt Perform
Jun-21-19Initiated H.C. Wainwright Buy $17
Jul-13-20 04:05PM  
Iterum Therapeutics Informs Shareholders of Record Date for Planned Rights Offering
GlobeNewswire
Jun-30-20 09:12AM  
Iterum Therapeutics Announces $5 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
GlobeNewswire -16.20%
Jun-29-20 07:30AM  
Iterum Therapeutics Announces Topline Results from its Phase 3 Clinical Trial of Oral Sulopenem for the Treatment of Uncomplicated Urinary Tract Infections
GlobeNewswire -7.19%
Jun-15-20 04:30PM  
Iterum Therapeutics plc Announces Result of Proposal 8 at Annual General Meeting
GlobeNewswire
Jun-03-20 03:45PM  
Whats Next for Iterum (ITRM) After Sulopenem Fails Phase 3 Trial? Top Analyst Weighs In
TipRanks -8.02%
09:50AM  
Iterum Therapeutics Announces $5 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
GlobeNewswire
Jun-02-20 09:42AM  
Company News for June 2, 2020
Zacks
Jun-01-20 08:30AM  
Iterum Therapeutics Announces Topline Results for a Phase 3 Clinical Trial of Oral and IV Sulopenem in Complicated Urinary Tract Infection
GlobeNewswire -59.62%
May-14-20 09:31AM  
3 Biotech Stocks Under $4 That Could Surge Over 50%
TipRanks
06:45AM  
Iterum Therapeutics Reports First Quarter 2020 Financial Results
GlobeNewswire
Apr-09-20 04:05PM  
Iterum Therapeutics to Present at the 19th Annual Needham Virtual Healthcare Conference
GlobeNewswire
Mar-31-20 07:00AM  
Iterum Therapeutics Provides Update on Phase 3 Clinical Trials of Sulopenem in Complicated Urinary Tract Infection (cUTI) and Uncomplicated Urinary Tract Infection (uUTI)
GlobeNewswire
Mar-12-20 06:45AM  
Iterum Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results
GlobeNewswire -9.85%
Feb-19-20 07:30AM  
Iterum Therapeutics to Present at the 9th Annual SVB Leerink Global Healthcare Conference
GlobeNewswire +10.96%
Jan-17-20 06:15AM  
Iterum Therapeutics Announces $52 Million Private Placement with New and Existing Investors
GlobeNewswire -26.01%
Jan-03-20 03:15PM  
Riding December's Momentum Into 2020
Benzinga
Dec-26-19 05:00PM  
Iterum Therapeutics Announces Completion of Enrollment in Phase 3 Clinical Trial of Oral Sulopenem in Uncomplicated Urinary Tract Infection
GlobeNewswire
Dec-12-19 09:42AM  
Iterum Down as Sulopenem Antibiotic Fails in Phase III Study
Zacks -7.05%
Dec-11-19 07:21AM  
The Daily Biotech Pulse: Correvio Faces FDA Panel Rejection, Iterum's Antibiotic Trial Narrowly Misses Primary Endpoint
Benzinga -35.67%
Dec-10-19 04:10PM  
Iterum Therapeutics Announces Topline Results from Phase 3 Clinical Trial of Oral and IV Sulopenem for the Treatment of Complicated Intra-abdominal Infections
GlobeNewswire +21.86%
Nov-30-19 10:18AM  
Is Iterum Therapeutics plc (ITRM) Going To Burn These Hedge Funds ?
Insider Monkey
Nov-18-19 07:30AM  
Iterum Therapeutics Announces Completion of Enrollment in Phase 3 Clinical Trial of Oral and IV Sulopenem in Complicated Urinary Tract Infection
GlobeNewswire +5.97%
Nov-12-19 07:05PM  
Iterum Therapeutics PLC (ITRM) Reports Q3 Loss, Lags Revenue Estimates
Zacks +5.65%
04:30PM  
Iterum Therapeutics Reports Third Quarter 2019 Financial Results and Highlights
GlobeNewswire
Nov-08-19 01:01PM  
What Kind Of Shareholders Own Iterum Therapeutics plc (NASDAQ:ITRM)?
Simply Wall St. +12.11%
Nov-06-19 10:30AM  
Earnings Preview: Iterum Therapeutics PLC (ITRM) Q3 Earnings Expected to Decline
Zacks -6.76%
Oct-01-19 10:07AM  
Antimicrobials Working Group Highlights Member Company Participation at IDWeek 2019
PR Newswire
Sep-27-19 04:30PM  
Iterum Therapeutics to Present at the Cantor Fitzgerald Global Healthcare Conference
GlobeNewswire
Sep-09-19 03:24PM  
If You Had Bought Iterum Therapeutics (NASDAQ:ITRM) Stock A Year Ago, You'd Be Sitting On A 17% Loss, Today
Simply Wall St. -8.91%
Aug-14-19 08:15AM  
Iterum Therapeutics PLC (ITRM) Reports Q2 Loss, Misses Revenue Estimates
Zacks -11.04%
07:00AM  
Iterum Therapeutics Reports Second Quarter 2019 Financial Results
GlobeNewswire
Aug-06-19 10:30AM  
Iterum Therapeutics PLC (ITRM) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
Zacks
Aug-01-19 07:30AM  
Iterum Therapeutics to Present at the Canaccord Genuity 39th Annual Growth Conference
GlobeNewswire
Jul-10-19 12:13PM  
Who Has Been Buying Iterum Therapeutics plc (NASDAQ:ITRM) Shares?
Simply Wall St.
Jul-01-19 09:13AM  
X-Biotix Therapeutics Joins Antimicrobials Working Group
PR Newswire -7.70%
Jun-21-19 07:30AM  
Iterum Therapeutics to Present Data on Uncomplicated Urinary Tract Infections at ASM Microbe 2019
GlobeNewswire
Jun-20-19 11:13AM  
Antimicrobials Working Group Highlights Member Company Participation at ASM Microbe 2019
PR Newswire
Jun-07-19 09:27AM  
Antimicrobials Working Group Commends Senator Isakson and Senator Casey for Introducing Legislation to Improve Access to Innovative Therapies to Fight Drug-Resistant Infections
PR Newswire -9.54%
May-14-19 07:00AM  
Iterum Therapeutics Reports First Quarter 2019 Financial Results
GlobeNewswire
Apr-12-19 10:08AM  
Antimicrobials Working Group Highlights Member Company Participation at the 29th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
PR Newswire
Apr-11-19 07:30AM  
Iterum Therapeutics Presents Data on Risks for Treatment Failure Associated with Uncomplicated Urinary Tract Infection and Activity of its Novel Antibiotic Sulopenem at ECCMID 2019
GlobeNewswire
Mar-28-19 09:00AM  
Iterum Therapeutics PLC (ITRM) Moves to Buy: Rationale Behind the Upgrade
Zacks
08:27AM  
Will Iterum Therapeutics Continue to Surge Higher?
Zacks
Mar-25-19 07:00AM  
Iterum Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results
GlobeNewswire +10.18%
Mar-19-19 07:00AM  
Iterum Therapeutics Receives QIDP for Oral and IV Sulopenem in Four Additional Indications as well as Fast Track Designation
GlobeNewswire +23.21%
Feb-21-19 10:15AM  
What Kind Of Shareholders Own Iterum Therapeutics plc (NASDAQ:ITRM)?
Simply Wall St.
Feb-19-19 07:30AM  
Iterum to Present at the 8th Annual SVB Leerink Partners Global Healthcare Conference
GlobeNewswire
Jan-17-19 10:00AM  
Antimicrobials Working Group Announces Updates to Leadership Team
PR Newswire
Dec-20-18 12:36PM  
Are Insiders Buying Iterum Therapeutics plc (NASDAQ:ITRM) Stock?
Simply Wall St. -8.71%
Nov-14-18 07:15AM  
Iterum Reports Third Quarter 2018 Financial Results and Recent Highlights
GlobeNewswire -10.46%
Nov-05-18 04:05PM  
Iterum Therapeutics plc to Participate in Investor Conferences in November and December
GlobeNewswire
Oct-05-18 08:00AM  
Iterum Therapeutics Presents Data Highlighting Antibiotic Sulopenem at IDWeek 2018
GlobeNewswire
Sep-25-18 04:05PM  
Iterum to Present at Cantor Fitzgerald Global Healthcare Conference
GlobeNewswire -5.66%
Sep-20-18 08:00AM  
Iterum Therapeutics to Present Clinical Data on Antibiotic Sulopenem at IDWeek 2018
GlobeNewswire -16.83%
Sep-18-18 08:00AM  
Iterum Initiates SURE 2 and SURE 3 Phase 3 Clinical Trials of IV and Oral Sulopenem in Complicated Urinary Tract and Complicated Intra-abdominal Infections
GlobeNewswire
Aug-14-18 07:30AM  
Iterum Reports Second Quarter 2018 Financial Results and Recent Highlights
GlobeNewswire
Aug-09-18 04:05PM  
Iterum Initiates SURE 1, a Phase 3 Clinical Trial of Oral Sulopenem in Uncomplicated Urinary Tract Infections
GlobeNewswire
Jun-06-18 10:08AM  
Antimicrobials Working Group Highlights Member Company Participation at ASM Microbe 2018
PR Newswire
08:00AM  
Iterum Therapeutics to Present Data on Prevalence of Resistant Infections and In Vitro Activity of its Novel Antibiotic Sulopenem
PR Newswire
May-25-18 12:51AM  
[$$] Drugmaker Iterum Therapeutics Bags $80 Million in IPO
The Wall Street Journal
May-24-18 08:15PM  
Iterum Therapeutics Announces Pricing of Initial Public Offering
PR Newswire
Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing anti-infectives for multi-drug resistant pathogens in Ireland and the United States. The company is developing sulopenem, a novel penem anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. Iterum Therapeutics plc was founded in 2015 and is headquartered in Dublin, Ireland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Sofinnova Venture Partners IX,10% OwnerJun 02Sale1.61400,000642,9601,226,514Jun 03 08:20 PM
Sofinnova Venture Partners IX,10% OwnerJun 01Sale1.69100,000169,1201,626,514Jun 03 08:20 PM
open in yahoo | open in reuters | open in google